These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28899685)

  • 1. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
    Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
    J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
    Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
    Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
    Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
    J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
    Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
    J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 6. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
    Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
    Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
    Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
    Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
    J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
    Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W
    Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
    Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
    Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 signaling pathways.
    Yi C; Zhang Y; Yu Z; Xiao Y; Wang J; Qiu H; Yu W; Tang R; Yuan Y; Guo W; Deng W
    PLoS One; 2014; 9(7):e99943. PubMed ID: 25000190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.
    Che Y; Li Y; Zheng F; Zou K; Li Z; Chen M; Hu S; Tian C; Yu W; Guo W; Luo M; Deng W; Zou L
    Cancer Lett; 2019 Jun; 452():1-13. PubMed ID: 30905820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
    Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
    J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
    Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance.
    Avitan-Hersh E; Feng Y; Oknin Vaisman A; Abu Ahmad Y; Zohar Y; Zhang T; Lee JS; Lazar I; Sheikh Khalil S; Feiler Y; Kluger H; Kahana C; Brown K; Ruppin E; Ronai ZA; Orian A
    J Invest Dermatol; 2020 Dec; 140(12):2466-2477. PubMed ID: 32360601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.